Search Results

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) MOA: Capivasertib is an oral pan-AKT inhibitor Key Eligibility Criteria: Men and women with adv/metastatic HR+/HER2- breast cancer Pre-/perimenopausal…

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy  (eVOLVE-HNSCC) MOA: Checkpoint inhibitor Volrustomig (MEDI5752): Monovalent, bispecific, anti-PD-1 / anti-CTLA-4 humanized IgG1 mAb Key Eligibility Criteria: Locally advanced squamous…

Marissa Davidson, DNP, earned her associate degree in nursing at Morrisville State University, where she was awarded the Distinguished Nurse Award for academic excellence. She then went on to earn a bachelor’s degree in nursing at Chamberlain University. In May 2024, she graduated from the University of Maryland School of Nursing with a Doctor of…

Caroline Wiseman, MSN, AGPCNP, has worked in nursing since 2009 and has practiced as a nurse practitioner since 2015. Caroline received a bachelor’s degree in nursing from James Madison University before attending the George Washington University for her Master of Science in Nursing. She is certified as an adult and gerontology primary care nurse practitioner…

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) MOA: TX-080 is an anti-HLA-G antibody that binds specifically to HLA-G and blocks engagement with ILT2 and ILT4 and reverses HLA-G-mediated immunosuppression. Key Eligibility Criteria: Histologically or…